Sanofi
Anti-TGF-beta antibodies and their use
Last updated:
Abstract:
The invention provides an improved pan-TGF-.beta. antibody for treatment of conditions that are mediated by TGF-.beta., including autoimmune diseases, fibrotic conditions, and cancers. Also provided are methods and uses of the antibody in conjunction with other immunomodulatory agents such as an anti-PD-1 antibody.
Status:
Grant
Type:
Utility
Filling date:
16 Jul 2020
Issue date:
8 Feb 2022